{"entity":{"id":"nct07145255","kind":"trial","name":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ADC in prostate cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by MBrace Therapeutics, now recruiting.","summary":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT07145255 by MBrace Therapeutics, with 150 participants planned, started 2025-09-03 and due to reach its primary completion in 2029-09-30. Interventions recorded: ADC.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07145255","url":"https://clinicaltrials.gov/study/NCT07145255"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["mbrace-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07145255","phase":"1/2","setting":"A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors","sponsor":"MBrace Therapeutics","enrolled":150,"outcomes":[]},"route":"/trials/nct07145255/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"mbrace-therapeutics","kind":"company","name":"MBrace Therapeutics","route":"/companies/mbrace-therapeutics/"}]}}